Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer

Authors:
  • TAT. Ahlert
    T. Ahlert
  • WSW. Sauerbrei
    W. Sauerbrei
  • GBG. Bastert
    G. Bastert
  • SRS. Ruhland
    S. Ruhland
  • BBB. Bartik
    B. Bartik
  • NSN. Simiantonaki
    N. Simiantonaki
  • JSJ. Schumacher
    J. Schumacher
  • BHB. Hacker
    B. Hacker
  • MSM. Schumacher
    M. Schumacher
  • VSV. Schirrmacher
    V. Schirrmacher

Abstract
The April 1997 article entitled, "Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer" by Ahlert et al (J Clin Oncol 15:1354–1366, 1997) contained several errors. On page 1354, the affiliation should have read: from the Universität-Frauenklinik Heidelberg; Deutsches Krebsforschungszentrum Heidelberg, Abteilung 710; Forschungspraxis Technologiepark Heidelburg; Institute für medizinische Biometrie und Informatik, Universität Freiburg, Freiburg, Germany. Reference number 36 on page 1365 should have read: 36. Pomer S, Schirrmacher V, Thiele R, et al: Tumor response and 4-year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous r-IL-2 and IFN-alpha 2b. Int J Oncol 6:941–954, 1995 In addition, Table 5 is reprinted here correctly in its entirety: Please see the PDF for table 5.